C6orf118

Across TCGA pan-cancer cohorts, C6orf118 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated C6orf118 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher C6orf118 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated C6orf118 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, ESCA, and STAD are the cancer types where C6orf118 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.614	.001	36	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	27	view →
STAD	DFS	Median	III,IV	1.000	0.333	.021	8	view →
PRAD	DFS	Median	All	0.086	0.776	<.001	6	view →
LUSC	OS	Median	III,IV	0.231	0.678	.004	6	view →
LIHC	OS	Median	All	0.098	0.774	.001	6	view →
BLCA	OS	Median	IV	0.132	0.599	.004	3	view →
LUAD	DFS	Median	All	0.153	0.360	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

C6orf118–UCEC (DFS)

Open the UCEC breakdown →